Welcome to our dedicated page for Ekso Bionics Holdings news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics Holdings stock.
Ekso Bionics Holdings, Inc. (Symbol: EKSO) is a pioneering company in the field of robotic exoskeletons, or wearable robots, aimed at augmenting human strength, endurance, and mobility. Since its founding in 2005, Ekso Bionics has developed cutting-edge technology that has enabled thousands of people with paralysis to take millions of steps that would otherwise be impossible. Headquartered in Richmond, California, with international offices in London, the company has been a leader in both the healthcare and industrial markets.
Ekso Bionics operates through two main segments: EksoHealth and EksoWorks. The EksoHealth segment, which generates the majority of the company's revenue, focuses on designing, engineering, manufacturing, and selling exoskeletons for medical applications. These devices are worn over clothing and controlled by trained operators to assist individuals with mobility challenges. The EksoWorks segment, on the other hand, targets able-bodied users by creating exoskeleton devices that help them perform strenuous, repetitive tasks for extended periods.
Over the years, Ekso Bionics has been at the forefront of innovation, continuously pushing the boundaries of what robotic exoskeletons can achieve. Their products have not only redefined the scope of physical rehabilitation but have also found significant applications in various industrial settings, allowing workers to carry out challenging tasks more efficiently. Ekso Bionics is committed to breaking physical limitations and helping users reach new heights of capability.
For the latest updates, partnerships, and developments related to Ekso Bionics and their stock performance, visit StockTitan regularly.
Ekso Bionics Holdings announced a significant partnership with the Fraternal Order of Eagles to enhance patient care in Nebraska. The EksoNR devices will be donated to Bryan Medical Center and Nebraska Methodist Hospital, benefiting over 60% of patients. This innovative technology aims to improve rehabilitation outcomes for patients with spinal cord injuries, strokes, and brain injuries. The initiative underscores Ekso's commitment to advanced rehabilitation and support for healthcare providers.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported a revenue of $3.0 million for Q3 2021, a slight increase from $2.9 million in Q3 2020. The gross margin was approximately 59%, down from 63% the previous year. The company booked 16 EksoNR units and maintained a strong cash position of $43.4 million. Despite increased revenues from EksoHealth, the net loss applicable to common stockholders for the quarter was $2.0 million, contrasting with a net income of $2.5 million during the same period in 2020.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q3 2021 on November 2, after market close. Management will discuss these results in a conference call at 1:30 p.m. PT/4:30 p.m. ET. A live webcast will be accessible in the 'Investors' section on the company's website. For those unable to attend, a replay will be available for two weeks. Ekso Bionics specializes in exoskeleton solutions for medical and industrial applications, enhancing strength and mobility for users.
Ekso Bionics Holdings, listed on Nasdaq as EKSO, announced its participation in a fireside chat at the H.C. Wainwright 23rd Annual Global Investor Conference from September 13-15, 2021. The chat will be available on-demand starting at 4:00 AM PT / 7:00 AM ET on September 13, allowing investors to access insights into the company's exoskeleton technology for medical and industrial purposes. Founded in 2005, Ekso Bionics focuses on innovative solutions to enhance mobility and strength.
Ekso Bionics Holdings reported Q2 2021 revenue of $2.2 million, slightly down from $2.3 million in Q2 2020. The gross margin improved to approximately 58% from 56% year-over-year, driven by better margins on EksoWorks products. Notably, the company successfully booked 20 EksoNR units, including 11 subscriptions. Despite an increased net loss of $1.3 million compared to $11.8 million in Q2 2020, the company holds a strong cash position of $45.9 million as of June 30, 2021, indicating stable financial health.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its Q2 2021 financial results on July 29, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results and recent business developments. Investors can access a live webcast on the company's website. A replay will be available for two weeks post-call. Ekso Bionics specializes in exoskeleton technology for medical and industrial applications, aiming to enhance human capabilities. The company is headquartered in the San Francisco Bay Area.
Ekso Bionics (Nasdaq: EKSO) has expanded its partnership with Kindred Healthcare by introducing the EksoNR robotic exoskeleton in four Long-Term Acute Care hospitals in Florida. Following a successful pilot program, this expansion aims to improve patient recovery from serious injuries and illnesses, including strokes and spinal cord injuries. The EksoNR has been recognized for its effectiveness in rehabilitation, and its deployment in these hospitals reflects a commitment to enhancing patient care. This strategic move is expected to bolster Ekso's presence in the healthcare market.
Ekso Bionics reported a 30% revenue increase for Q1 2021, totaling $1.9 million, compared to $1.5 million in Q1 2020. The company achieved a record gross margin of 65%, up from 43% year-over-year. Cash reserves surged to $49.5 million from $12.9 million at the end of 2020, bolstered by a $40 million public offering. The subscription model has facilitated sales to key rehabilitation operators, indicating strong market traction. However, a net loss of $3.7 million was recorded, compared to $2.5 million in the previous year.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q1 2021 after market close on April 29, 2021. A conference call will follow at 1:30 p.m. PT to discuss these results and recent developments. Investors can access the call via phone or through a live webcast on the company’s website. A replay will be available for two weeks post-call. Founded in 2005, Ekso Bionics specializes in exoskeleton solutions that enhance strength and mobility for medical and industrial applications.
Ekso Bionics Holdings (Nasdaq: EKSO) has announced a partnership with U.S. Physiatry (USP) to educate healthcare professionals on the clinical benefits of the EksoNR exoskeleton. USP, the largest physician practice focused on physical medicine in the U.S., will conduct a four-part lecture series aimed at enhancing the integration of Ekso's technology into rehabilitation programs. The initiative seeks to raise awareness and promote the economic value of the EksoNR, which is noted as the most studied exoskeleton available, potentially benefiting thousands of patients.
FAQ
What is the current stock price of Ekso Bionics Holdings (EKSO)?
What is the market cap of Ekso Bionics Holdings (EKSO)?
What does Ekso Bionics Holdings, Inc. do?
Where is Ekso Bionics headquartered?
What are the main segments of Ekso Bionics?
What does the EksoHealth segment specialize in?
What does the EksoWorks segment focus on?
How has Ekso Bionics impacted people with paralysis?
In which regions does Ekso Bionics operate?
How can I get in touch with Ekso Bionics for investor relations?
What innovations has Ekso Bionics brought to the industrial market?
How does Ekso Bionics contribute to physical rehabilitation?
